An Open Label, Phase I Study to Evaluate the Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation Positive Cancer Patients

Trial Profile

An Open Label, Phase I Study to Evaluate the Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation Positive Cancer Patients

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Jul 2017

At a glance

  • Drugs Vemurafenib (Primary)
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Roche
  • Most Recent Events

    • 05 Jul 2017 Planned End Date changed from 1 Nov 2016 to 14 Jul 2017.
    • 05 Jul 2017 Status changed from recruiting to active, no longer recruiting.
    • 27 Jan 2014 Planned End Date changed from 1 Jul 2019 to 1 Nov 2016 as reported by ClinicalTrials.gov record..
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top